Pliant ends development of idiopathic pulmonary fibrosis asset bexotegrast
Source: SeekingAlpha
2025-06-27 16:32:50 ET
More on Pliant Therapeutics
- Pliant Therapeutics: An Activist On Deck
- Pliant Therapeutics to trim about 45% of workforce
- Seeking Alpha’s Quant Rating on Pliant Therapeutics
- Historical earnings data for Pliant Therapeutics
- Financial information for Pliant Therapeutics
Read the full article on Seeking Alpha
For further details see:
Pliant ends development of idiopathic pulmonary fibrosis asset bexotegrast
Pliant Therapeutics Inc.
NASDAQ: PLRX
PLRX Trading
1.5% G/L:
$1.355 Last:
15,580 Volume:
$1.33 Open:
PLRX Latest News
March 11, 2026 04:05:00 pm
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
February 23, 2026 08:00:00 am
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
PLRX Stock Data
$72,817,521
56,533,434
3.63%
28
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
